The 22 analysts offering 12-month price forecasts for Neurocrine Biosciences Inc have a median target of 121.50, with a high estimate of 145.00 and a low estimate of 90.00. The median estimate represents a +3.79% increase from the last price of 117.06.
The current consensus among 25 polled investment analysts is to Buy stock in Neurocrine Biosciences Inc. This rating has held steady since January, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share $0.60
Reporting Date Feb 05
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.